EP Patent

EP2210585A1 — SPRM pharmaceutical compositions methods of treatment using them

Assigned to Exelgyn · Expires 2010-07-28 · 16y expired

What this patent protects

The invention aims at providing novel compositions comprising Selective Progesterone Receptor Modulator (SPRM) and novel methods of treatment using them, which have the ability to prevent the intake of the composition by the patient in an abortive amount and avoid their misuse.

USPTO Abstract

The invention aims at providing novel compositions comprising Selective Progesterone Receptor Modulator (SPRM) and novel methods of treatment using them, which have the ability to prevent the intake of the composition by the patient in an abortive amount and avoid their misuse.

Drugs covered by this patent

Patent Metadata

Patent number
EP2210585A1
Jurisdiction
EP
Classification
Expires
2010-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Exelgyn
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.